

Pancreatic Cancer Committee meeting 11 Day 1 & 2

Date: 12/10/2017 & 13/10/2017

Location: RCOG, London

Minutes: Confirmed

Committee members present:		
John Primrose (Chair)		(Attended item 1 – 16)
Fiona Campbell		(Attended item 1 – 16)
Richard Charnley		(Attended item 1 – 16)
Pippa Corrie		(Attended item 1 – 12)
Lesley Goodburn		(Attended item 5 – 16)
Philip Whelan		(Attended item 1 – 16)
Derek O'Reilly		(Attended item 1 – 16)
Kofi Oppong		(Attended item 1 – 16)
Anna Jewell		(Attended item 1 – 16)
Margred Capel		(Attended item 1 – 16)
Suzanne Joharchi		(Attended item 1 - 16)
Mark Callaway		(Attended item 11 - 16)
Laura McGeeney		(Attended item 1 – 16)
Somnath Mukherjee		(Attended item 1 – 16)

In attendance:		
James Hall	NICE Editor	(Attended item 1 – 16)
Adam Storrow	NICE Business Analyst	(Attended item 1-9)
Katharina Dworzynski	NGA Guideline Lead	(Attended item 1 – 16)
John Graham	NGA Clinical Advisor	(Attended item 11 - 16)
James Hawkins	NGA Health Economist	(Attended item 4)
Jose Marcano-Belisario	NGA Senior Systematic Reviewer	(Attended item 1 – 16)
Ferruccio Pelone	NGA Systematic Reviewer	(Attended item 1 – 16)
Lin Fou	NGA Systematic Reviewer	(Attended item 1 - 16)
Michaela Dijmarescu	NGA Project Manager	(Attended item 1 – 16)
Observers:		

Apologies:	
Andrew Harding	NICE Commissioning Manager
Dawn Elliott	Committee member
John Graham	NGA Clinical Advisor (for Day 1 of the meeting)
Mark Callaway	Committee Member (for Day 1 of the meeting)
Pippa Corrie	Committee Member (for Day 2 of the meeting)

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 11th and final meeting on Pancreatic Cancer.

No members of the public were asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included two important updates on PET and neoadjuvant therapies. Alongside these, the stakeholders' comments and the responses need to be reviewed and signed off by the committee for the final submission.

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was pancreatic cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. With regards to PET-PANC, the Chair has asked the authors on this papers (Richard Charnley and Fiona Campbell) to not participate in the discussion.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation	Honorarium for speaking at Pancreatic Cancer Update, Preston 04/10/2017 from Mylan [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate

	Trust			
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Travel, accommodation to speak at BSG Pancreatic Cyst workshop, London 25/9/2017 [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Travel, accommodation to speak on Acute Pancreatitis at Emergency Surgical Conference, Oxford, 18/09/2017 [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Travel & accommodation to attend Precision–Panc launch meeting, Glasgow, 24/07/2017 [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Travel & accommodation to attend Oncology Forum, Birmingham 15-16/06/2017 [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Derek	Consultant	Travel &	Personal	Declare and

O'Reilly	Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	accommodation to attend LIMAX (Liver function) workshop, Mainz, Germany, 22/05/2017, from HuMedics. [DOI 11/10/2017]	financial, non-specific	participate
Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	Co-author on PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality ¹⁸ fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. [16/10/2017]	Personal non-financial, specific.	Declare and participate in the meeting, but Chair asked Mr Charnley to not participate in the drafting of the recommendations.
Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	I am a co-author on the submitted HTA report for the PET-PANC trial. [16/10/2017]	Personal non-financial, specific.	Declare and participate in the meeting, but Chair asked Dr. Campbell to not participate in the drafting of the recommendations.

3. Minutes of last meeting

The Chair welcomed the committee and notified the committee of apologies that had been received.

He asked the committee whether the minutes of the previous meeting were accurate. They agreed and minutes were signed-off.

The committee confirmed that all actions from the last meeting had been completed.

4. Presentations

The Chair introduced Katharina Dworzynski, Guideline Lead, who gave an overview on the agenda, the phase of the guideline process and next steps.

The Chair introduced Linyun Fou, Systematic Reviewer (attending in person) and James Hawkins, Health Economist, who presented an evidence update. The Chair introduced Linyun Fou, Systematic Reviewer, who presented the evidence update related to neoadjuvant therapy. The committee discussed the evidence and the impact on recommendations.

Katharina Dworzynski led a discussion on stakeholder comments and their impact on recommendations or other guideline documents was assessed by the committee and where necessary documents were revised.

Katharina Dworzynski outlined the content of the NICE publication policy.

The meeting concluded on the first day (Thu 12th Oct) at 16:30PM.

The Chair opened the second day of the meeting (Fri 13th Oct) and notified members of any apologies.

Linyun Fou, presented an evidence update related to stakeholder comments. . The committee discussed the evidence and the impact on recommendations.

The Chair then opened the meeting to any other stakeholder comments that had not yet been discussed and documents were revised where necessary.

The Committee then discussed possible publications resulting from the guideline.

5. Questions and discussion

The Committee discussed stakeholder comments as described above.

6. Any other business

No other business was raised.

Date of next meeting: This was the final GC Meeting.

Location of next meeting: This was the final GC Meeting.

